Publication
Title
Poly(I:C) as cancer vaccine adjuvant : knocking on the door of medical breakthroughs
Author
Abstract
Although cancer vaccination has yielded promising results in patients, the objective response rates are low. The right choice of adjuvant might improve the efficacy. Here, we review the biological rationale, as well as the preclinical and clinical results of polyinosinic:polycytidylic acid and its derivative poly-ICLC as cancer vaccine adjuvants. These synthetic immunological danger signals enhanced vaccine-induced anti-tumor immune responses and contributed to tumor elimination in animal tumor models and patients. Supported by these results, poly-ICLC-containing cancer vaccines are currently extensively studied in the ongoing trials, making it highly plausible that poly-ICLC will be part of the future approved cancer immunotherapies.
Language
English
Source (journal)
Pharmacology and therapeutics. - Oxford
Publication
Oxford : Pergamon-elsevier science ltd, 2015
ISSN
0163-7258
Volume/pages
146(2015), p. 120-131
ISI
000349504500009
Full text (Publisher's DOI)
Full text (open access)
Full text (publisher's version - intranet only)
UAntwerpen
Faculty/Department
Research group
[E?say:metaLocaldata.cgzprojectinf]
In vivo non invasive imaging of immunotherapy for acute myeloid leukemia in mice.
Publication type
Subject
Affiliation
Publications with a UAntwerp address
External links
Web of Science
Record
Identification
Creation 19.01.2015
Last edited 13.11.2017
To cite this reference